Replies to post #2412 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA updated corporate slide set (4/18/23):

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

There are only two differences between the between the 4/18/23 slide set and the previous version (dated 2/7/23):

• Slide 12 has minor changes about competing RSV drug candidates, mainly that the Ark Bio (China) fusion inhibitor, AK-059 is under review by China’s FDA (https://arkbiosciences.com/en_2022n/114 ).

• Slide 22 has an additional bullet point noting that EDP-235 has an FDA Fast Track designation.

Note: ENTA’s partial monetization of the Mavyret royalty stream on 4/25/23 is too recent to be incorporated in the slide set.